136 related articles for article (PubMed ID: 11186242)
21. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol influences platinum pharmacokinetics: A novel mechanism in protection against cisplatin-induced nephrotoxicity.
Darwish MA; Abo-Youssef AM; Khalaf MM; Abo-Saif AA; Saleh IG; Abdelghany TM
Toxicol Lett; 2018 Jun; 290():73-82. PubMed ID: 29574132
[TBL] [Abstract][Full Text] [Related]
23. [Prophylactic effect of methylprednisolone on cisplatin-induced nephrotoxicity].
Koikawa Y
Fukuoka Igaku Zasshi; 1995 Feb; 86(2):31-9. PubMed ID: 7729781
[TBL] [Abstract][Full Text] [Related]
24. Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity.
Sahu BD; Rentam KK; Putcha UK; Kuncha M; Vegi GM; Sistla R
Food Chem Toxicol; 2011 Dec; 49(12):3090-7. PubMed ID: 21930180
[TBL] [Abstract][Full Text] [Related]
25. Time-dependent nephrotoxicity associated with daily administration of cisplatin in mice.
To H; Kikuchi A; Tsuruoka S; Sugimoto K; Fujimura A; Higuchi S; Kayama F; Hara K; Matsuno K; Kobayashi E
J Pharm Pharmacol; 2000 Dec; 52(12):1499-504. PubMed ID: 11197078
[TBL] [Abstract][Full Text] [Related]
26. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
Nagai N; Ogata H; Wada Y; Tsujino D; Someya K; Ohno T; Masuhara K; Tanaka Y; Takahashi H; Nagai H; Kato K; Koshiba Y; Igarashi T; Yokoyama A; Kinameri K; Kato T; Kurita Y
J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
[TBL] [Abstract][Full Text] [Related]
27. Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats.
Osman NM; Copley MP; Litterst CL
Cancer Chemother Pharmacol; 1984; 13(1):58-62. PubMed ID: 6428763
[TBL] [Abstract][Full Text] [Related]
28. The effects of platinum levels in plasma, urine, and kidney on blood urea nitrogen levels after cisplatin injection in rats.
Uozumi J; Litterst CL
J Pharmacobiodyn; 1988 Apr; 11(4):277-83. PubMed ID: 3411443
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
[TBL] [Abstract][Full Text] [Related]
31. Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.
Eiseman JL; Beumer JH; Rigatti LH; Strychor S; Meyers K; Dienel S; Horn CC
Cancer Chemother Pharmacol; 2015 Jan; 75(1):143-52. PubMed ID: 25398697
[TBL] [Abstract][Full Text] [Related]
32. Effects of betamipron on cisplatin nephrotoxicity and its pharmacokinetics in rats.
Tokunaga J; Kobayashi M; Kitagawa A; Nakamura C; Arimori K; Nakano M
Biol Pharm Bull; 1997 Apr; 20(4):386-91. PubMed ID: 9145215
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of vitamin E and C on cisplatin nephrotoxicity in developing rats.
Appenroth D; Fröb S; Kersten L; Splinter FK; Winnefeld K
Arch Toxicol; 1997; 71(11):677-83. PubMed ID: 9363840
[TBL] [Abstract][Full Text] [Related]
34. Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats.
Humanes B; Lazaro A; Camano S; Moreno-Gordaliza E; Lazaro JA; Blanco-Codesido M; Lara JM; Ortiz A; Gomez-Gomez MM; Martín-Vasallo P; Tejedor A
Kidney Int; 2012 Sep; 82(6):652-63. PubMed ID: 22718191
[TBL] [Abstract][Full Text] [Related]
35. The role of the renin-angiotensin system in cisplatin nephrotoxicity.
Deegan PM; Nolan C; Ryan MP; Basinger MA; Jones MM; Hande KR
Ren Fail; 1995 Nov; 17(6):665-74. PubMed ID: 8771239
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of CV247 against cisplatin nephrotoxicity in rats.
Máthé C; Szénási G; Sebestény A; Blázovics A; Szentmihályi K; Hamar P; Albert M
Hum Exp Toxicol; 2014 Aug; 33(8):789-99. PubMed ID: 23653282
[TBL] [Abstract][Full Text] [Related]
38. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
Helmy MM; Helmy MW; El-Mas MM
PLoS One; 2015; 10(11):e0142303. PubMed ID: 26536032
[TBL] [Abstract][Full Text] [Related]
39. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity.
Katsuda H; Yamashita M; Katsura H; Yu J; Waki Y; Nagata N; Sai Y; Miyamoto K
Biol Pharm Bull; 2010; 33(11):1867-71. PubMed ID: 21048313
[TBL] [Abstract][Full Text] [Related]
40. Effect of oral administration of Arabic gum on cisplatin-induced nephrotoxicity in rats.
Al-Majed AA; Abd-Allah AR; Al-Rikabi AC; Al-Shabanah OA; Mostafa AM
J Biochem Mol Toxicol; 2003; 17(3):146-53. PubMed ID: 12815610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
